Journal of Neuro-Oncology

, Volume 74, Issue 1, pp 31–40 | Cite as

Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells

  • Sean D. Mc AllisterEmail author
  • Calvin Chan
  • Ryan J. Taft
  • Tri Luu
  • Mary E. Abood
  • Dan H. Moore
  • Ken Aldape
  • Garret Yount
Laboratory Investigation


Normal tissue toxicity limits the efficacy of current treatment modalities for glioblastoma multiforme (GBM). We evaluated the influence of cannabinoids on cell proliferation, death, and morphology of human GBM cell lines and in primary human glial cultures, the normal cells from which GBM tumors arise. The influence of a plant derived cannabinoid agonist, Δ9-tetrahydrocannabinol Δ9-THC), and a potent synthetic cannabinoid agonist, WIN 55,212-2, were compared using time lapse microscopy. We discovered that Δ9-THC decreases cell proliferation and increases cell death of human GBM cells more rapidly than WIN 55,212-2. Δ9-THC was also more potent at inhibiting the proliferation of GBM cells compared to WIN 55,212-2. The effects of Δ9-THC and WIN 55,212-2 on the GBM cells were partially the result of cannabinoid receptor activation. The same concentration of Δ9-THC that significantly inhibits proliferation and increases death of human GBM cells has no significant impact on human primary glial cultures. Evidence of selective efficacy with WIN 55,212-2 was also observed but the selectivity was less profound, and the synthetic agonist produced a greater disruption of normal cell morphology compared to Δ9-THC.


cannabinoid Delta-9-tetrahydrocannabinol extracellular signal regulated kinases glioblastma multiforme time lapse microscopy 





extracellular signal regulated kinases


fetal bovine serum


glioblastoma multiforme


multivariate analysis of variance


mitogen-activated protein kinases




time lapse microscopy


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Guzman, M 2003Cannabinoids: potential anticancer agentsNat Rev Cancer3745755CrossRefPubMedGoogle Scholar
  2. 2.
    Mechoulam, R, Fride, E, Di Marzo, V 1998EndocannabinoidsEur J Pharmac359118CrossRefGoogle Scholar
  3. 3.
    Pertwee, RG 1997Pharmacology of cannabinoid CB1 and CB2 receptorsPharmacol Therap74129180CrossRefGoogle Scholar
  4. 4.
    Glass, M, McAllister, SD 2002Cannabinoid mediated signal transductionOnaivi, E eds. The Biology of Marijuana: From Gene to Behaviour.Harwood Academic PublishersReading, UKGoogle Scholar
  5. 5.
    Bifulco, M, Di Marzo, V 2002Targeting the endocannabinoid system in cancer therapy: a call for further researchNat Med8547550CrossRefPubMedGoogle Scholar
  6. 6.
    Guzman, M, Sanchez, , C, , Galve-Roperh, I 2002Cannabinoids and cell fatePharmacol Ther95175184CrossRefPubMedGoogle Scholar
  7. 7.
    Ruiz, L, Miguel, A, Diaz-Laviada, I 1999Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanismFEBS Lett458400404CrossRefPubMedGoogle Scholar
  8. 8.
    Massi, P, Vaccani, A, Ceruti, S, Colombo, A, Abbracchio, MP, Parolaro, D 2004Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell linesJ Pharmacol Exp Ther308838845CrossRefPubMedGoogle Scholar
  9. 9.
    Bifulco, M, Laezza, C, Portella, G, Vitale, M, Orlando, P, Petrocellis, L, Di Marzo, V 2001Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growthFASEB J1527452747PubMedGoogle Scholar
  10. 10.
    Casanova, ML, Blazquez, C, Martinez-Palacio, J, Villanueva, C, Fernandez-Acenero, MJ, Huffman, JW, Jorcano, JL, Guzman, M 2002Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptorsJ Clin Invest1114350CrossRefGoogle Scholar
  11. 11.
    Galve-Roperh, I, Sanchez, C, Cortes, ML, del Pulgar, TG, Izquierdo, M, Guzman, M 2000Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activationNat Med6313319CrossRefPubMedGoogle Scholar
  12. 12.
    Sanchez, C, Galve-Roperh, I, Canova, C, Brachet, P, Guzman, M 1998Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cellsFEBS Lett436610CrossRefPubMedGoogle Scholar
  13. 13.
    Velasco, G, Galve-Roperh, I, Sanchez, C, Blazquez, C, Guzman, M 2004Hypothesis: cannabinoid therapy for the treatment of gliomasNeuropharmacology47315323CrossRefPubMedGoogle Scholar
  14. 14.
    Murphy, S 1990Generation of astrocyte cultures from normal and neoplastic central nervous systemConn, PM eds. Methods in Neuroscineces: Cell Culture.Academic PressSan Diego, CA3347Google Scholar
  15. 15.
    Jacobsson, SO, Rongard, E, Stridh, M, Tiger, G, Fowler, CJ 2000Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viabilityBiochem Pharmacol6018071813CrossRefPubMedGoogle Scholar
  16. 16.
    Forrester, HB, Vidair, CA, Albright, N, Ling, CC, Dewey, WC 1999Using computerized video time lapse for quantifying cell death of X-irradiated rat embryo cells transfected with c-myc or c-Ha-rasCancer Res59931939PubMedGoogle Scholar
  17. 17.
    Sarker, KP, Obara, S, Nakata, M, Kitajima, I, Maruyama, I 2000Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3FEBS Lett4723944CrossRefPubMedGoogle Scholar
  18. 18.
    Showalter, VM, Compton, DR, Martin, BR, Abood, ME 1996Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligandsJ Pharmacol Exp Ther278989999PubMedGoogle Scholar
  19. 19.
    Felder, C, Mitchell, R 1995Comparison of the signal transduction of the human cannabinoid CB1 and CB2 receptorsASPET48443450Google Scholar
  20. 20.
    Breivogel, CS, Griffin, G, Di Marzo, V, Martin, BR 2001Evidence for a new G protein-coupled cannabinoid receptor in mouse brainMol Pharmacol60155163PubMedGoogle Scholar
  21. 21.
    Recht, LD, Salmonsen, R, Rosetti, R, Jang, T, Pipia, G, Kubiatowski, T, Karim, P, Ross, AH, Zurier, R, Litofsky, NS, Burstein, S 2001Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoidBiochem Pharmacol62755763CrossRefPubMedGoogle Scholar
  22. 22.
    Sanchez, C, Ceballos, ML, del Pulgar, TG, Rueda, D, Corbacho, C, Velasco, G, Galve-Roperh, I, Huffman, JW, Ramony Cajal, S, Guzman, M 2001Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptorCancer Res6157845789PubMedGoogle Scholar
  23. 23.
    Velasco, L, Ruiz, L, Sanchez, MG, Diaz-Laviada, I 2001Delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cellsInvolvement of CB1531535Google Scholar
  24. 24.
    Sanchez, MG, Sanchez, AM, Ruiz-Llorente, L, Diaz-Laviada, I 2003Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cellsFEBS Lett555561566CrossRefPubMedGoogle Scholar
  25. 25.
    Hart, S, Fischer, OM, Ullrich, A 2004Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptorCancer Res6419431950PubMedGoogle Scholar
  26. 26.
    Crowe, DL, Kim, R, Chandraratna, RA 2003Retinoic acid differentially regulates cancer cell proliferation via dose-dependent modulation of the mitogen-activated protein kinase pathwayMol Cancer Res1532540PubMedGoogle Scholar
  27. 27.
    Griffin, G, Atkinson, PJ, Showalter, VM, Martin, BR, Abood, ME 1998Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5’- O -(3-[35 S]thio)-triphosphate binding assay in rat cerebellar membranesA NAME=”OLE” J Pharmacol Exp Ther285553560Google Scholar
  28. 28.
    Breivogel, CS, Selley, DE, Childers, SR 1998Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinityJ Biol Chem2731686516873CrossRefPubMedGoogle Scholar
  29. 29.
    Song, Z, Bonner, TI 1995A lysine residue of the cannabinoid receptor is critical for recptor recognition by several agonist but not WIN 55,212-2Mol Pharmacol49891896Google Scholar
  30. 30.
    McAllister, SD, Rizvi, G, Anavi-Goffer, S, Hurst, DP, Barnett-Norris, J, Lynch, DL, Reggio, PH, Abood, ME 2003An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding regionJ Med Chem4651395152CrossRefPubMedGoogle Scholar
  31. 31.
    Liu, J, Li, H, Burstein, SH, Zurier, RB, Chen, JD 2003Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acidMol Pharmacol63983992CrossRefPubMedGoogle Scholar
  32. 32.
    Blazquez, C, Gonzalez-Feria, L, Alvarez, L, Haro, A, Casanova, ML, Guzman, M 2004Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomasCancer Res6456175623PubMedGoogle Scholar
  33. 33.
    Kleinberg, LR, Weingart, J, Burger, P, Carson, K, Grossman, SA, Li, K, Olivi, A, Wharam, MD, Brem, H 2004Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient managementCancer Invest2219CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Sean D. Mc Allister
    • 1
    Email author
  • Calvin Chan
    • 1
  • Ryan J. Taft
    • 1
  • Tri Luu
    • 1
  • Mary E. Abood
    • 1
  • Dan H. Moore
    • 1
    • 2
  • Ken Aldape
    • 3
  • Garret Yount
    • 1
  1. 1.California Pacific Medical Center Research InstituteSan FranciscoUSA
  2. 2.Department of Epidemiology and BiostatisticsUniversity of California San FranciscoSan FranciscoUSA
  3. 3.Department of PathologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations